Amicus price target lowered to $18 from $19 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Amicus to $18 from $19 and keeps an Overweight rating on the shares. The firm’s estimates are in line with consensus on Galafold revenues and Pombiliti plus Opfolda revenues, the analyst tells investors in a preview note. The firm will be looking out for updates on the Pombiliti plus Opfolda launch and whether the company is tracking to full-year non-GAAP profitability, the analyst added.